MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why CANF Stock advanced +0.61% Today — RQD Quant Desk Flash
$1.66 +0.61% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.66
Can-Fite Biopharma Ltd each representing two (2) (CANF) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $5.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CANF Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CANF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Can-Fite Biopharma Ltd each representing two (2) (NYSE: CANF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.66 (+0.61% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CANF ranks #938 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CANF compare to ADXN and XBIO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CANF carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ADXN (Addex Therapeutics Ltd) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $5.0M) and XBIO (Xenetic Biosciences Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M). Among the 5-stock peer group, CANF leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CANF?
▼
Per CANF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001536196), Can-Fite Biopharma Ltd each representing two (2) generated $405.0K in revenue (-39.9% YoY), -$9.8M in net income, and -$9.0M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.66 (-0.08%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CANF)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY CANF SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (26% of score)
20D Institutional Volume Accumulation (±10.7% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 23.6 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.90-7.4% Next Q
39
Q2 (-2Q)Grade E$1.76+1.1% Next Q
36
Q3 (-1Q)Grade E$1.78-6.7% Next Q
34
CurrentGrade E$1.66-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CANF Turnaround Squeeze
While CANF currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.74) forces dealer call-delta covering toward $13.02.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CANF• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CANF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CANF Stock advanced +0.61% Today — RQD Quant Desk Flash
Can-Fite Biopharma Ltd each representing two (2) (CANF) advanced +0.61% to $1.66, trading at 2% of its 52-week range ($1.6 – $12.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.6 – $12.4) with RSI-14 at 23.6 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $1.66 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CANF Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CANF)
- ✓Walkthrough of CANF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CANF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.96%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.68H $1.70L $1.60C $1.66VOL 22.4K
SUP: $1.55SMA50: $2.26SMA200: $3.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CANF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CANF today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CANF. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CANF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CANF)
Health Care Rank #938 of 1016
⚔️ ADXN vs CANF Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CANF vs. ADXN, XBIO, APUS, PULM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Can-Fite Biopharma Ltd each representing two (2) (CANF) ranks #938 by composite RQD confidence (31/100, grade E) and #946 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, CANF leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with CANF at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CANF
ACTIVE
Can-Fite Biopharma Ltd each representing two (2) | E | 31/100 | — | — | -35.0% | +0.61% | $5.0M | Benchmark Subject |
| ADXN Addex Therapeutics Ltd | D+ | 57/100 | — | — | — | -1.01% | $5.0M | /adxn-vs-canf → |
| XBIO Xenetic Biosciences Inc. | D | 47/100 | — | — | -30.3% | +0.95% | $5.0M | /xbio-vs-canf → |
| APUS Apimeds Pharmaceuticals US Inc. | D- | 43/100 | — | — | -6.2% | +4.56% | $5.0M | /apus-vs-canf → |
| PULM Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -5.67% | $5.2M | /pulm-vs-canf → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001536196In its most recent audited fiscal period (FY2025, filed 2025-12-31), Can-Fite Biopharma Ltd each representing two (2) (CANF) reported GAAP revenue of $405.0K (-39.9% vs. FY2024 revenue of $674.0K , and -45.5% cumulative change since FY2023) , GAAP net income of -$9.8M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-17.1% YoY). On the balance sheet, CANF closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $405.0K | -$9.8M | -$8.9M | -$9.0M | $9.5M | — |
| FY2024 (FY) | 2024-12-31 | $674.0K | -$7.9M | -$7.6M | -$7.6M | $9.1M | — |
| FY2023 (FY) | 2023-12-31 | $743.0K | -$7.6M | -$8.4M | -$8.4M | — | — |
3. CANF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CANF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Can-Fite Biopharma Ltd each representing two (2) (NYSE: CANF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.66 (+0.61% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CANF ranks #938 in composite RQD confidence.
How does CANF compare to ADXN and XBIO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CANF carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ADXN (Addex Therapeutics Ltd) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $5.0M) and XBIO (Xenetic Biosciences Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M). Among the 5-stock peer group, CANF leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CANF?
Per CANF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001536196), Can-Fite Biopharma Ltd each representing two (2) generated $405.0K in revenue (-39.9% YoY), -$9.8M in net income, and -$9.0M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CANF trading relative to its 50-day, 200-day, and 52-week technical levels?
CANF last traded at $1.66 (+0.61% on volume of 22,039 shares), positioning the stock -26.55% below its 50-day simple moving average ($2.26) and -48.29% below its 200-day simple moving average ($3.21). Across its 52-week range of $1.60 to $12.40, CANF sits at the 0.6% percentile with a 14-day RSI of 23.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.48 to $1.84).
CANF Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CANF stock moving today?
Why CANF Stock advanced +0.61% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.